Monoclonal antibodies (McAbs) allow the precise definition of individual components of complex antigenic structures, such as tumour cell surfaces. Mouse and rat monoclonal antibodies raised against human tumour cells have identified molecules that are present in greater quantity on tumours when compared with normal cells (Lennox & Sikora, 1982; Marx, 1982) . Such antibodies have already been shown to have clinical use in diagnosis by providing markers of tumour load (Koprowski et al., 1981) , and for radiolocalisation of tumour deposits (Mach et al., 1982) . Promising preliminary results in therapeutic trials with these antibodies in patients with colorectal cancer (Sears et al., 1982) and nodular lymphoma (Miller et al., 1982) have recently been reported. A major problem with such antibodies has been their lack of specificity. Although the target antigens recognised may often be expressed in increased quantities on tumour cells, most McAbs show no absolute tumour specificity (Brown et al., 1981; Lennox & Sikora, 1982) . Many of the antigens are present in small quantities on stem cells in normal tissue. The xenogeneic immunisation schedules used in the preparation of these McAbs emphasise certain components on the cell surface such as the blood group substances and histocompatibility antigens which are shared by normal and neoplastic cells. A further problem with xenogeneic McAbs is the immune response to them when used clinically, which may abrogate their effects. Furthermore, no information may be derived about the way in which the host's immune system is responding to the presence of autologous tumour.
There is considerable evidence that patients are able to mount a serological response to their own neoplastic cells, at least at some stages of the natural history of their disease (Shiku et al., 1977) . By fusing lymphocytes likely to be involved in this response with a suitable myeloma line, hybridomas can be produced and antibody activity analysed. There have been several reports of hybrid cell lines generated by fusion of human lymphocytes to mouse and rat myelomas (Table I) . Indeed a McAb against a measles virus antigen has been produced in this way using lymphocytes from a patient infected with the virus (Croce et al., 1980) . Such inter-species hybrids shed human chromosomes preferentially, so rapidly losing the ability to immortalise human immunoglobulin genes from the donor lymphocytes. Although early and repetitive cloning of the hybrids can reduce the shedding of human chromosomes (Wunderlich et al., 1981) , it is clear that the development of a stable human hybridoma system using a suitable human myeloma would be of advantage. Several human systems have now been described in the literature (Table II) . We have chosen to use the LICR-LON HMy2 line in our attempts to make human McAbs to a wide range of tumour types using lymphocytes from several sources. Peripheral blood, regional lymph node, and intra-tumoural lymphocytes have been collected and fused. After cloning, the supernatants were screened for anti-tumour activity on cell lines. This paper reports our attempts to make human anti-tumour monoclonal antibodies from material from 180 patients. Hales (1977) . An 8-azaguanine (8 AG) resistant human lymphoid cell line, LICR-LONHMy2 (Edwards et al., 1982) , was used which was sensitive to hypoxanthine, aminopterin and thymidine (HAT) medium. This line was adapted for growth on serum-free medium and cloned. Several clones were tested for fusion with peripheral blood lymphocytes and one LICR-LONHMy2/CAMI (subsequently referred to as HMy2) chosen for further study. For each fusion, the recovered lymphocytes and a constant number of 5 x 107 myeloma cells were suspended in serum-free Dulbecco's modified eagles medium (DMEM), mixed, and centrifuged at 1500rpm for 10min in a 50ml conical-bottomed plastic centrifuge tube. The supernatant was drained off completely. Five hundred microlitres of PEG M.W. 1000, 41.7% (w/v), with 15% dimethyl sulphoxide (DMSO) in serum-free DMEM was added to the pellet, and the cells gently resuspended using the tip of the pipette. After 1 min, 0.5 ml of PEG 1000, 33% (w/v) in serum-free DMEM, but without DMSO, was added, and the mixture stirred gently for 3min.
Four millilitres of DMEM with 10% foetal calf serum (FCS) was added dropwise, and the mixture rocked for a further 4min. Forty-five ml of DMEM with 10% FCS was slowly added, and the mixture was taken up carefully in a wide bore 25 ml pipette, and dispensed equally into each of 96 (2ml) wells of 4 Linbro plates. One ml of DMEM with 10% FCS was added to each well, and renewed after 2 h. After 24h, the medium was partly replaced by selected medium containing HAT 20% FCS (Miller & Ruddle, 1976) . The selective medium was renewed daily for at least the first 2 weeks. Hybrid clones visibly appeared in some wells between 3-6 weeks after fusion. Supernatants from well-grown wells were taken for testing, supplemented with 10mM Hepes buffer and 0.1% sodium azide, and stored at 4°C. Bulk supernatants from cloned hybrids growing in roller bottles were in Iscove's (Flow Laboratories) (Iscove & Melchers, 1978) serum-free medium supplemented with 5 pg ml-1 of insulin. Bulk supernatants were harvested and concentrated using Millipore CX-10 (10,000 daltons exclusion) ultrafiltration unit.
Immunoglobulin (Ig) assay Rabbit anti-human Ig antisera (Miles Laboratories) was diluted in phosphate buffered saline (PBS) to 1/1000. Fifty A aliquots were added to roundbottomed 96-well vinyl plastic plates and incubated overnight at 4°C. These plates were subsequently washed in medium containing Earle's buffered salt solution, 1% bovine serum albumin, 0.01% sodium -azide, adjusted to pH 7.4 by 1 M sodium hydroxide. After washing 4 x by decanting the contents of the wells and replacing with a 5Oyl of medium, the plates were left for 1 h at room temperature and again washed as previously described. Fifty pl of chain-specific monoclonal mouse anti-human Ig was added (Bethesda Research Laboratories) at a concentration of 1/5000. After 1 h incubation with the relevant monoclonal antibodies, the plates were washed and rat anti-mouse Ig coupled to I125 using the chloramine-T method was added. After a final incubation of 1 h and 4 subsequent washes in complete medium, the plates were air dried, the wells cut with a hot wire, and counted in a y counter.
Surface typing of hybridomas This was carried out by indirect immunofluorescence (Dorreen et al., 1982 cellsml-'. Cells were pelleted and resuspended in ethidium bromide (0.05 mg ml -1) in hypotonic (0.1%) sodium citrate. DNA histograms were obtained by means of a custom-built flow cytometer which incorporated an argon laser (Watson, 1981) . Rudland); and the MRC5 fibroblast line. Freshly trypsinised cells were washed 3 x by centrifugation and suspended in assay medium identical with that used for Ig typing. Viable cells were counted by trypanblue exclusion and adjusted to a concentration of 2 x 106 ml-'. Fifty ,ul of cell suspension was placed into each well of round-bottomed Cooke microtitre plates which had been previously incubated overnight with 50 4l well of poly L-lysine in phosphate buffered saline at 37°C. The cells were fixed for 1 h in 0.25% glutaraldehyde and washed 3 x in medium. Fifty ,l of supernatant was added and incubated at room temperature for 1 h. After washing three times 50 pl of mouse anti-human light chain antibody at a dilution of 1/5000 was added and incubated for 1 h. The final stage of the assay was the addition of 50 pl radioiodinated rabbit antimouse Ig. After a further hour the cells were washed and counted on a y counter.
Results

Cell fusion
Clinical material was obtained from 180 patients with a variety of tumours over the course of 1 year (Table III) . Apparently successful initial fusion was observed in 55 patients. Low lymphocyte yields and infection were the major problems in the early stages. Infection was a particular hazard in samples from patients with colorectal carcinoma where lymph nodes and contaminated large bowel were placed in a single sterile container for delivery to the laboratory. Cloned hybrids were obtained in 24 patients. Hybrids appeared between 4-8 weeks following fusion and were seen as clumps of piledup cells amongst the debris of dying normal lymphocytes and HMy2 cells (Figure 1 ). Once established, hybridomas were rapidly growing with doubling times of 24-36h. All hybrids tested were easily adapted for growth in serum-free (Iscoves) medium in 41 roller bottles.
Ig secretion All hybridomas continued to produce the K and y chains secreted by HMy2. In addition, 14% produced A chains, 15% p chains, 13% a chains and 1% e chains ( Table 4 ). The production of new Igs continued after prolonged tissue culture. One-5 ,ugIgml-' was detected in the supernatants. Figure 2 shows the flow cytometry analysis of surface Ig content detected by polyclonal rabbit anti-human Ig. Peripheral blood lymphocytes show a slight increase over the HMy2 content of surface Ig. All hybrids tested show a considerable increase in the amount of Ig expressed.
Lymphocyte antigens and human hybridomas
DNA content Figure 3 shows the DNA content of lymphocytes, HMy2 and one hybridoma. The DNA content of the hybrid cell is approximately the sum of that of the parent myeloma, plus that of the lymphocytes. After 8 months of continuous culture, no change was observed in this increased DNA content.
Electron microscopy Figure 4 shows electron microscopy of HMy2 and a resultant hybridoma, LGLL-lD6. The endoplasmic reticulum was poorly developed.
Anti-tumour antibody activity and specificity Antibodies were initially screened for binding activity against the cell line most appropriate to the HMy 2 source of donor lymphocyte. An initial screen of 40 hybridoma supernatants is shown in Figure 5 . Despite the sensitivity of the binding assay, the counts bound were low. After concentration, however, (Figure 6 ), titration curves were obtained. These curves show only weak binding of antibody. However the binding was significantly above LYMPH background when compared to that of HMy2 Ig at similar concentration ( Figure 6 ). The specificity of binding was determined using several tumour cell lines (Table VI) . Peripheral blood lymphocytes and red blood cells from normal donors were used as controls. It can be seen that all the antibodies isolated so far bind to a variety of cell types and LGLI-lD6 LGLI-1D6 DNA content which confirm a stably increased chromosome number (Edwards et al., 1982) .
There molecules comprised of chains coded by both myeloma or lymphocyte genes will occur. Such molecules will have reduced antibody activity. A third problem is the low antibody secretion rate of between I and 51tgml-'. Large amounts of tissue culture supernatant must be concentrated in order to increase signal-to-noise ratio in the radioimmunoassay.
The poorly developed endoplasmic reticulum in all hybrids examined by electron microscopy suggests that the rate of protein synthesis may well be limiting. The initial screen for anti-tumour antibody activity may be unable to detect the small amounts of weak antibodies. Finally, the low anti-tumour binding activity hinders the analysis of specificity of the resulting antibodies. A combination of low secretion 
